Home / Tag Archives: Vaccine

Tag Archives: Vaccine

CSRA’s DynPort Vaccine Company Gets Orphan Drug Designation on Plague Vaccine

TYSONS CORNER, VA, March 10, 2017 — A subsidiary of CSRA (NYSE: CSRA) has secured orphan drug status from the Food and Drug Administration on a plague vaccine it is developing as a potential pre-exposure prophlaxis treatment against Yersinia pestis infection, ExecutiveBiz reported Thursday. The company said Wednesday the designation enables DynPort Vaccine Company to …

Read More »

Leidos to Help Develop Vaccine for Zika Virus; Jerry Hogge Comments

TYSONS CORNER, VA, April 11, 2016 — Leidos (NYSE: LDOS) will work with Immunovaccine to develop a vaccine that aims to prevent the spread of the mosquito-borne Zika virus, ExecutiveBiz reported Friday. The companies will integrate Immunovaccine’s DepoVax platform and Leidos’ Virtual Pharmaceutical Development Program in support of efforts to accelerate vaccine development and production, …

Read More »

CDC Awards Emergent BioSolutions New Anthrax Vaccine Development Funds

The Department of Health and Human Services has tapped Emergent BioSolutions to further develop a new anthrax vaccine under a 30-month, $31 million contract with funding and technical support from the Biomedical Advanced Research and Development Authority. HHS said Monday the new vaccine, called NuThrax, will work to improve on the existing licensed vaccine as …

Read More »

HHS Taps Profectus BioSciences for Ebola, Marburg Vaccine R&D

The Department of Health and Human Services has awarded Profectus BioSciences an $8.6 million contract to further develop and test a vaccine designed to treat infections caused by Ebola and Marburg viruses. HHS said Tuesday the cost-plus-fixed-fee contract covers research and development of Profectus’ Ebola and Marburg filovirus vaccine rVSVN4CT1. …

Read More »

Emergent BioSolutions Gets $1.25 Billion Contract to Supply Anthrax Vaccine

The U.S. government has selected Emergent BioSolutions Inc. (NYSE: EBS) to supply millions of doses of its anthrax vaccine over five years on a contract worth up to $1.25 billion. Contract work will begin this year and calls for Emergent to deliver a total of 44.75 million doses of BioThrax. In the …

Read More »